rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
1998-5-13
|
pubmed:abstractText |
The distinction between malignant mesothelioma (MM) and adenocarcinoma (ACA) in cytologic specimens frequently is difficult, often requiring immunocytochemistry to support the diagnosis. Recent reports have proposed the utilization of antibodies to mesothelial cell clone HBME-1 and thrombomodulin (TM), because they are immunoreactive in MM and less commonly reactive in ACA. Immunoreactivity for the monoclonal antibody CA 19-9 has been observed in many ACAs and reportedly is absent in MM.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0008-543X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
25
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
101-8
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9570213-Adenocarcinoma,
pubmed-meshheading:9570213-Antibodies, Monoclonal,
pubmed-meshheading:9570213-Antigens, Neoplasm,
pubmed-meshheading:9570213-Biopsy, Needle,
pubmed-meshheading:9570213-CA-19-9 Antigen,
pubmed-meshheading:9570213-Diagnosis, Differential,
pubmed-meshheading:9570213-False Positive Reactions,
pubmed-meshheading:9570213-Humans,
pubmed-meshheading:9570213-Immunohistochemistry,
pubmed-meshheading:9570213-Mesothelioma,
pubmed-meshheading:9570213-Pleural Effusion,
pubmed-meshheading:9570213-Pleural Neoplasms,
pubmed-meshheading:9570213-Sensitivity and Specificity,
pubmed-meshheading:9570213-Thrombomodulin
|
pubmed:year |
1998
|
pubmed:articleTitle |
Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology.
|
pubmed:affiliation |
Laboratory of Pathology, Cytopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1500, USA.
|
pubmed:publicationType |
Journal Article
|